{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:36:12Z","timestamp":1793478972244,"version":"4.5.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171768"],"award-info":[{"award-number":["82171768"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3602000"],"award-info":[{"award-number":["2022YFC3602000"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Polymyalgia rheumatica (PMR) is a common inflammatory disease in elderly persons whose mechanism of pathogenesis has not been elucidated. Glucocorticoids are the main first-line treatments but result in numerous side effects. Therefore, there is a need to explore pathogenetic factors and identify possible glucocorticoid-sparing agents. We aimed to study the pathogenetic features of the disease and assess the efficacy and safety of Janus tyrosine kinase (JAK)-inhibitor tofacitinib in patients with PMR.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>We recruited treatment-na\u00efve PMR patients from the First Affiliated Hospital, Zhejiang University School of Medicine, between September 2020 and September 2022. In the first cohort, we found that the gene expression patterns of peripheral blood mononuclear cells (PBMCs) in 11 patients (10 female, 1 male, age 68.0 \u00b1 8.3) with newly diagnosed PMR were significantly different from 20 healthy controls (17 female, 3 male, age 63.7 \u00b1 9.8) by RNA sequencing. Inflammatory response and cytokine\u2013cytokine receptor interaction were the most notable pathways affected. We observed marked increases in expression of IL6R, IL1B, IL1R1, JAK2, TLR2, TLR4, TLR8, CCR1, CR1, S100A8, S100A12, and IL17RA, which could trigger JAK signaling. Furthermore, tofacitinib suppressed the IL-6R and JAK2 expression of CD4<jats:sup>+<\/jats:sup>T cells from patients with PMR <jats:italic>in vitro<\/jats:italic>.<\/jats:p>\n<jats:p>In the second cohort, patients with PMR were randomized and treated with tofacitinib or glucocorticoids (1\/1) for 24 weeks. All PMR patients underwent clinical and laboratory examinations at 0, 4, 8, 12, 16, 20, and 24 weeks, and PMR activity disease scores (PMR-AS) were calculated. The primary endpoint was the proportion of patients with PMR-AS \u226410 at weeks 12 and 24. Secondary endpoints: PMR-AS score, c-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) at weeks 12 and 24. Thirty-nine patients with newly diagnosed PMR received tofacitinib, and 37 patients received glucocorticoid. Thirty-five patients (29 female, 6 male, age 64.4 \u00b1 8.4) and 32 patients (23 female, 9 male, age 65.3 \u00b1 8.7) patients completed the 24-week intervention, respectively. There were no statistically significant differences in primary or secondary outcomes. At weeks 12 and 24, all patients in both groups had PMR-AS &lt;10. PMR-AS, CRP, and ESR were all significantly decreased in both groups. No severe adverse events were observed in either group. Study limitations included the single-center study design with a short observation period.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We found that JAK signaling was involved in the pathogenesis of PMR. Tofacitinib effectively treated patients with PMR as glucocorticoid does in this randomized, monocenter, open-label, controlled trial (ChiCTR2000038253).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>This investigator-initiated clinical trial (IIT) had been registered on the website (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/\" xlink:type=\"simple\">http:\/\/www.chictr.org.cn\/<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\/showproj.html?proj=61426\" xlink:type=\"simple\">ChiCTR2000038253<\/jats:ext-link>).<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004249","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T17:39:00Z","timestamp":1688060340000},"page":"e1004249","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2577-8436","authenticated-orcid":true,"given":"Xinlei","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7809-8288","authenticated-orcid":true,"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-5923","authenticated-orcid":true,"given":"Yiduo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-0966","authenticated-orcid":true,"given":"Chuanying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4048-5501","authenticated-orcid":true,"given":"Lanlan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4204-2407","authenticated-orcid":true,"given":"Chunyun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-7841","authenticated-orcid":true,"given":"Weiqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"issue":"9","key":"pmed.1004249.ref001","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41584-020-0458-5","article-title":"Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica","volume":"16","author":"D Camellino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"pmed.1004249.ref002","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jama.2020.10155","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis","volume":"324","author":"F Buttgereit","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"pmed.1004249.ref003","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2021.1890032","article-title":"Predicting the risk of relapse in polymyalgia rheumatica: novel insights","volume":"17","author":"D Prieto-Pe\u00f1a","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"pmed.1004249.ref004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4081\/reumatismo.2018.1048","article-title":"Pathogenesis of polymyalgia rheumatica","volume":"70","author":"G Guggino","year":"2018","journal-title":"Reumatismo"},{"issue":"3","key":"pmed.1004249.ref005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/ard-2022-222873","article-title":"Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica","volume":"82","author":"WF Jiemy","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"pmed.1004249.ref006","doi-asserted-by":"crossref","first-page":"102670","DOI":"10.1016\/j.autrev.2020.102670","article-title":"The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle","volume":"19","author":"G Carvajal Alegria","year":"2020","journal-title":"Autoimmun Rev"},{"key":"pmed.1004249.ref007","article-title":"Genetically proxied IL-6 receptor inhibition and risk of polymyalgia rheumatica","author":"SS Zhao","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pmed.1004249.ref008","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"M Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pmed.1004249.ref009","first-page":"e27606","article-title":"Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?","volume":"14","author":"M Farinango","year":"2022","journal-title":"Cureus"},{"issue":"11","key":"pmed.1004249.ref010","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial","volume":"328","author":"V Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"pmed.1004249.ref011","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jama.2022.11526","article-title":"Tocilizumab as a Novel Therapy for Steroid-Dependent Polymyalgia Rheumatica","volume":"328","author":"B. Antiochos","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"pmed.1004249.ref012","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: a 10-year epidemiologic and clinical study","volume":"97","author":"TY Chuang","year":"1982","journal-title":"Ann Intern Med"},{"issue":"4","key":"pmed.1004249.ref013","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"B Dasgupta","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"10","key":"pmed.1004249.ref014","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica","volume":"63","author":"BF Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pmed.1004249.ref015","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.21769\/BioProtoc.323","article-title":"Isolation of Human PBMCs","volume":"3","author":"SK Panda","year":"2013","journal-title":"Bio-protocol"},{"key":"pmed.1004249.ref016","unstructured":"Quick start guide. HyLown. 2022. http:\/\/www.powerandsamplesize.com\/Calculators\/."},{"issue":"12","key":"pmed.1004249.ref017","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1002\/art.27728","article-title":"Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica","volume":"62","author":"F Kreiner","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pmed.1004249.ref018","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-Induced JAK\/STAT Signaling Is Antagonized by TGF\u03b2 to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma","volume":"9","author":"G Biffi","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"pmed.1004249.ref019","doi-asserted-by":"crossref","first-page":"e108466","DOI":"10.1371\/journal.pone.0108466","article-title":"Formal modelling of toll like receptor 4 and JAK\/STAT signalling pathways: insight into the roles of SOCS-1, interferon-\u03b2 and proinflammatory cytokines in sepsis","volume":"9","author":"RZ Paracha","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"pmed.1004249.ref020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1189\/jlb.1206763","article-title":"Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation","volume":"82","author":"X Hu","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"45","key":"pmed.1004249.ref021","doi-asserted-by":"crossref","first-page":"34773","DOI":"10.1074\/jbc.M110.133884","article-title":"C\/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity","volume":"285","author":"C Zannetti","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"pmed.1004249.ref022","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cbf.3482","article-title":"IL6 inhibition of inflammatory S100A8\/9 proteins is NF-\u03baB mediated in essential thrombocythemia","volume":"38","author":"M Dikli\u0107","year":"2020","journal-title":"Cell Biochem Funct"},{"issue":"2","key":"pmed.1004249.ref023","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2003.08.021","article-title":"The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages","volume":"171","author":"T Hasegawa","year":"2003","journal-title":"Atherosclerosis"},{"issue":"10","key":"pmed.1004249.ref024","doi-asserted-by":"crossref","first-page":"9125","DOI":"10.18632\/aging.103180","article-title":"Cigarette smoke-induced lung inflammation in COPD mediated via CCR1\/JAK\/STAT \/NF-\u03baB pathway","volume":"12","author":"K Zhao","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"pmed.1004249.ref025","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1002\/art.11344","article-title":"Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis","volume":"48","author":"S Shahrara","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"58","key":"pmed.1004249.ref026","doi-asserted-by":"crossref","first-page":"eabg0833","DOI":"10.1126\/sciimmunol.abg0833","article-title":"SARS-CoV-2 drives JAK1\/2-dependent local complement hyperactivation","volume":"6","author":"B Yan","year":"2021","journal-title":"Sci Immunol"},{"issue":"11","key":"pmed.1004249.ref027","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"M Samson","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pmed.1004249.ref028","doi-asserted-by":"crossref","first-page":"102995","DOI":"10.1016\/j.autrev.2021.102995","article-title":"Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review","volume":"21","author":"E Hysa","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"4","key":"pmed.1004249.ref029","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"C Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"pmed.1004249.ref030","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis","volume":"137","author":"H Zhang","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"pmed.1004249.ref031","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard-2022-223562","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study","volume":"82","author":"L Zhang","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"pmed.1004249.ref032","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/annrheumdis-2021-eular.3435","article-title":"AB0379 Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases","volume":"80","author":"D Camellino","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pmed.1004249.ref033","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"SR Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004249.ref034","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"C Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"pmed.1004249.ref035","doi-asserted-by":"crossref","first-page":"e1003432","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study","volume":"17","author":"M Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"issue":"10","key":"pmed.1004249.ref036","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"C Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T17:39:32Z","timestamp":1688060372000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004249","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}